Clinical Stage Partnering Agreements in Biopharma : Market Research Report

Clinical Stage Partnering Agreements in Biopharma

Published: Jun. 1, 2008 - 440 Pages

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in clinical stage dealmaking: 2.1. Introduction; 2.2. Difference between phase I, II and III stage deals; 2.3. Trends in phase I deals since 2000; 2.4. Trends in phase II deals since 2000; 2.5. Trends in phase III deals since 2000; 2.6. Reasons for entering into clinical stage partnering deals; 2.7. The future of clinical stage partnering deals
Chapter 3 - Overview of clinical stage deal structure: 3.1. Introduction; 3.2. Pure versus multi-component partnering deals; 3.3. Pure licensing agreement structure; 3.4. Multicomponent clinical stage partnering agreements
Chapter 4 - Leading phase I clinical stage deals: 4.1. Introduction; 4.2. Top phase I clinical stage deals by value; 4.3. Top phase I clinical stage deals signed by bigpharma; 4.4. Most active phase I clinical stage dealmakers; 4.5. Bigpharma phase I clinical stage deal activity
Chapter 5 - Leading phase II clinical stage deals: 5.1. Introduction; 5.2. Top phase II clinical stage deals by value 70; 5.3. Top phase II clinical stage deals signed by bigpharma; 5.4. Most active phase II clinical stage dealmakers; 5.5. Bigpharma phase II clinical stage deal activity
Chapter 6 - Leading phase III clinical stage deals: 6.1. Introduction; 6.2. Top phase III clinical stage deals by value; 6.3. Top phase III clinical stage deals signed by bigpharma; 6.4. Most active phase III clinical stage dealmakers; 6.5. Bigpharma phase III clinical stage deal activity
Chapter 7 - Bigpharma clinical stage partnering agreements: 7.1. Introduction; 7.2. How to use clinical stage partnering agreements; 7.3. Company clinical stage partnering agreement listings
Chapter 8 - Phase I partnering agreement directory 2003-early 2008: 8.1. Introduction; 8.2. Company A-Z; 8.3. By therapy area; 8.4. By deal type
Chapter 9 - Phase II partnering agreement directory 2003-early 2008: 9.1. Introduction; 9.2. Company A-Z; 9.3. By therapy area; 9.4. By deal type
Chapter 10 - Phase III agreement directory 2003-early 2008: 10.1. Introduction; 10.2. Company A-Z; 10.3. By therapy area; 10.4. By deal type
Appendices: Appendix 1 - Clinical stage partnering references; Appendix 2 - Resources; Appendix 3 - Deal type definitions; Appendix 3 - Deal type definitions; Appendix 4 - Example clinical stage partnering contract; About CurrentPartnering; Recent report titles from CurrentPartnering; Order Form - Reports; Order form - Company Dealmaking Profiles
Table of figures: Figure 1: Definition of clinical phases in dealmaking; Figure 2: Trends in clinical stage deal announcements, 2000-2007; Figure 3: Trends in phase I deal announcements, 2000-2007; Figure 4: Trends in phase II deal announcements, 2000-2007; Figure 5: Trends in phase III deal announcements, 2000-2007; Figure 6: Components of the pure licensing deal structure; Figure 7: Top phase I clinical stage deals by value since 2003; Figure 8: Bigpharma - top 50 - phase I clinical stage deals since 2003; Figure 9: Most active phase I clinical stage dealmakers 2003-early 2008; Figure 10: Bigpharma - top 50 - phase I clinical stage deals since 2003; Figure 11: Top phase II clinical stage deals by value since 2003; Figure 12: Bigpharma - top 50 - phase II clinical stage deals since 2003; Figure 13: Most active phase II clinical stage dealmakers 2003-early 2008; Figure 14: Bigpharma - top 50 - phase II clinical stage deals since 2003; Figure 15: Top phase III clinical stage deals by value since 2003; Figure 16: Bigpharma - top 50 - phase III clinical stage deals since 2003; Figure 17: Most active phase III clinical stage dealmakers 2003-early 2008; Figure 18: Bigpharma - top 50 - phase III deals since 2003; Figure 19: Online partnering resources; Figure 20: Deal type definitions; Figure 21: Partnering agreement between Alfacell and Par - Jan 2008

Abstract

The Clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the clinical stage agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter clinical stage partnering deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1000 links to online copies of actual clinical stage contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of clinical stage dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in clinical stage partnering as well as a discussion on the merits and attributes of dealmaking at each stage of clinical development.

Chapter 3 provides an overview of the structure of clinical stage partnering deal contracts. The chapter includes numerous case studies to enable understanding of both pure deals and multicomponent clinical stage partnering deals.

Chapters 4, 5 and 6 provide a review of the leading phase I, II and III clinical stage partnering deals since 2000, respectively. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of clinical stage contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapters 8, 9 and 10 provide a comprehensive listing of all phase I, II and III clinical stage agreement contracts since 2003 available in the public domain, respectively. Each chapter is organized by A-Z, therapeutic area, and deal type. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about clinical stage partnering, enabling thorough learning, education and due diligence prior and during the clinical stage dealmaking process.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Clinical Stage Partnering Agreements in Biopharma

Table of Contents

Abstract